CLINICAL OUTCOMES AND ADVERSE DRUG REACTIONS IN COVID-19 PATIENTS TREATED WITH HYDROXYCHLOROQUINE AND AZITHROMYCIN ALONE OR COMBINED

Authors

DOI:

https://doi.org/10.11603/ijmmr.2413-6077.2021.1.11814

Keywords:

hydroxychloroquine, azithromycin, SARS CoV-2

Abstract

Background. Use of Hydroxychloroquine with or without Azithromycin is repurposed in SARS-CoV-2 in the absence of definitive treatment.

Objective. To evaluate the association between the use of Hydroxychloroquine and Azithromycin when given alone or in combination on clinical outcomes and adverse drug reactions among lab confirmed SARS CoV-2 positive patients admitted in a COVID tertiary care hospital of a University Medical college.

Methods. a retrospective observational comparative study was conducted. COVID-19 positive patients admitted in study hospital for management of COVID-19 were enrolled into the study. The patients were categorized into 4 treatment groups based on having received the following treatment during hospitalization: (A) Hydroxychloroquine with Azithromycin, (B) Hydroxychloroquine without Azithromycin (Hydroxychloroquine alone), (C) Azithromycin alone, and (D) Neither drug, defined as no receipt of either Hydroxychloroquine or Azithromycin in the record; other medications may have been dispensed.

Results. 800 patients were enrolled. Mean±Standard deviation of duration of hospital stay (in days) for study Group A was 11.37±7.11, for Group B was 8.37±4.77, for Group C was 18.22 ± 5.69 and for Group D was 6.12±2.97. Mortality in Group A was 29.74%, Group B – 33.16%, Group C – 0% and in Group D – 1.32%.

Conclusion. Among hospitalized patients with COVID-19 treatment, Group C was associated with good clinical outcome. However, the interpretation of these findings may be limited by the observational design.

Author Biographies

H. Rathi, RAJASTHAN UNIVERSITY OF HEALTH SCIENCES COLLEGE OF MEDICAL SCIENCES, JAIPUR (RAJASTHAN), INDIA

B.D.S, MSc. (med-pharmacology) 3rd year, Rajasthan University of Health Sciences College of Medical Sciences, Jaipur, India

P. Rathi, MAHATMA GANDHI MEDICAL COLLEGE, JAIPUR (RAJASTHAN), INDIA

Associate Professor, Mahatma Gandhi Medical College and Hospital, Jaipur, India

M. Biyani, SAWAI MAN SINGH MEDICAL COLLEGE, JAIPUR (RAJASTHAN), INDIA

M.B.B.S, M.D (Anaesthesia) 3rd year, Swai Man Singh Medical College, Jaipur, India

References

Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020 Feb 17:105924.

DOI: 10.1016/j.ijantimicag.2020.105924.

Wang LS, Wang YR, Ye DW, Liu QQ. A review of the 2019 Novel Coronavirus (COVID-19) based on current evidence”. Int J Antimicrob Agents 2020.

David N. Juurlink. Safety considerations with chloroquine, Hydroxychloroquine and Azithromycin in the management of SARS-CoV-2 infection. Canadian Medical Association Journal 2020;192 (17).

Wen Zhang et. al. The use of anti-inflammatory drugs in the treatment of people with severe coro­navirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clinical Immunology 2020; 214: 108393.

Shi et al. An overview of COVID-19. J Zhejiang Univ-Sci B (Biomed & Biotechnol) 2020;21(5):343-60.

Yamauchi K, Shibata Y, Kimura T, Abe S, Inoue S, Osaka D, et al. Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-gamma stimulated macrophages. Int J Biol Sci 2009;5(7):667-78.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lance 2020; 395(10223):497–506.

DOI: 0.1016/S0140-6736(20) 30183-5.

Silvano Esposito, Silvana Noviello, Pasquale Pagliano. Update on treatment of COVID-19: ongoing studies between promising and disappointing results. Le Infezioni in Medicina 2020; 2:198-211.

Samia Arshad et.al. Treatment with Hydro­xychloroquine, Azithromycin, and combination in patients hospitalized with COVID-19. International Journal of Infectious Diseases 2020;97:396-403.

Tran DH, Sugamata R, Hirose T, Suzuki S, Noguchi Y, Sugawara A, et al. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1) pdm09 virus infection by interfering with virus internalization process. J Antibiot 2019;72 (10):759–68.

DOI:10.1038/s41429-019-0204-x.

Matthieu Million et.al. Early treatment of COVID-19 patients with Hydroxychloroquine and Azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Medicine and Infectious Disease 2020:1-8.

Downloads

Published

2021-11-22

How to Cite

Rathi, H., Rathi, P., & Biyani, M. (2021). CLINICAL OUTCOMES AND ADVERSE DRUG REACTIONS IN COVID-19 PATIENTS TREATED WITH HYDROXYCHLOROQUINE AND AZITHROMYCIN ALONE OR COMBINED. International Journal of Medicine and Medical Research, 7(1), 20–27. https://doi.org/10.11603/ijmmr.2413-6077.2021.1.11814